首页> 外文期刊>BMC Infectious Diseases >The role of point-of-care viral load monitoring in achieving the target of 90% suppression in HIV-infected patients in Nigeria: study protocol for a randomized controlled trial
【24h】

The role of point-of-care viral load monitoring in achieving the target of 90% suppression in HIV-infected patients in Nigeria: study protocol for a randomized controlled trial

机译:护理病毒载量监测的作用在尼日利亚艾滋病毒感染患者中实现90%抑制的目标:随机对照试验的研究方案

获取原文
           

摘要

The Joint United Nations Programme on HIV/AIDS 90-90-90 goal envisions 90% of all people receiving antiretroviral therapy to be virally suppressed by 2020. Implied in that goal is that viral load be quantified for all patients receiving treatment, which is a challenging undertaking given the complexity and high cost of standard-of-care viral load testing methods. Recently developed point-of-care viral load testing devices offer new promise to improve access to viral load testing by bringing the test closer to the patient and also returning results faster, often same-day. While manufactures have evaluated point-of-care assays using reference panels, empiric data examining the impact of the new technology against standard-of-care monitoring in low- and middle-income settings are lacking. Our goal in this trial is to compare a point-of-care to standard-of-care viral load test on impact on various clinical outcomes as well to assess the acceptability and feasibility of using the assay in a resource-limited setting. Using a two-arm randomized control trial design, we will enroll 794 patients from two different HIV treatment sites in Nigeria. Patients will be randomized 1:1 for point-of-care or standard-of-care viral load monitoring (397 patients per arm). Following initiation of treatment, viral load will be monitored at patients' 6- and 12-month follow-up visits using either point-of-care or standard-of-care testing methods, based on trial assignment. The monitoring schedule will follow national treatment guidelines. The primary outcome measure in this trial is proportion of patients with viral suppression at month 12 post-initiation of treatment. The secondary outcome measures encompass acceptability, feasibility, and virologic impact variables. This clinical trial will provide information on the impact of using point-of-care versus standard-of-care viral load testing on patient clinical outcomes; the study will also supply data on the acceptability and feasibility of point-of-care viral load monitoring in a resource-limited setting. If this method of testing is acceptable and feasible, and also superior to standard of care, the results of the trial and the information gathered will inform future scaled implementation and further optimization of the clinic-laboratory network that is critical for monitoring achievement of the 90-90-90 goals. US National Institutes of Health Clinical Trials.gov: NCT03533868 . Date of Registration: 23 May 2018. Protocol Version: 10. Protocol Date: 30 March 2018.
机译:联合国艾滋病毒/艾滋病计划90-90-90的目标设想所有人的90%受到抗逆转录病毒疗法的2020人被2020年暗示的。在此目的是含有接受治疗的所有患者的病毒载量量化,这是一个鉴于经济标准病毒载量试验方法的复杂性和高成本,挑战性致力于承诺。最近开发的护理点病毒负载测试设备提供新的承诺,可以通过将测试更接近患者来改善对病毒负载测试的访问,并且还更快地返回结果,通常是同性。虽然制造商使用参考面板评估了护理点测定,但缺乏缺乏在低收入和中等收入环境中对新技术的影响对新技术的影响的验证数据。我们在该试验中的目标是对各种临床结果的影响,比较对各种临床结果的影响的护理点对重点,以及评估在资源限制环境中使用该测定的可接受性和可行性。使用双臂随机控制试验设计,我们将注册尼日利亚两种不同艾滋病治疗地点的794名患者。患者将被随机1:1进行护理点或护理标准病毒载荷监测(每只手臂397例)。在治疗开始之后,使用基于试验分配,在患者的6岁和12个月的后续访问中监测病毒载荷,并根据试验分配。监测时间表将遵循国家治疗指南。该试验中的主要结果措施是在12月12日疗法后的病毒抑制患者的比例。次要结果测量包括可接受性,可行性和病毒学影响变量。该临床试验将提供有关使用患者临床结果对患者临床结果的影响的影响的信息;该研究还将提供有关资源限制环境中护理点病毒负荷监测的可接受性和可行性的数据。如果这种测试方法是可接受的和可行的,并且还优于护理标准,则审判的结果和收集的信息将为未来的扩大实施以及进一步优化临床 - 实验室网络,这对于监测90的监测至关重要-90-90目标。美国国家健康研究院临床试验.GOV:NCT03533868。注册日期:2018年5月23日。议定书版:10。协议日期:2018年3月30日。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号